Mumbai, June 22, 2017: Pharma Major Lupin Limited (Lupin) announced today the launch of its Desoximetasone Cream USP, 0.05% and Desoximetasone Cream
USP, 0.25% having received an approval from the United States Food and Drug Administration (FDA) earlier.
Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% are the AB rated generic equivalent of Taro Pharmaceuticals North America, Inc’s Topicort® LP Emollient Cream, 0.05% and Taro Pharmaceuticals, Inc’s (collectively Taro) Topicort® Cream, 0.25%. Both products are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Topicort® LP Emollient Cream and Topicort® Cream had combined US sales of USD 38 million (IMS MAT April 2017).
Corporate Comm India(CCI Newswire)
Bangalore, September 20, 2024: Novo Nordisk Global Business Services (GBS) announced the launch of a…
Mumbai, September 20, 2024: MediBuddy, India’s largest digital healthcare platform, announced the launch of its…
Bangalore, September 19, 2024: Minimal Access Surgical Oncology Team at Fortis Hospital Bannerghatta Road achieved…
Partners with ARTIST Academy to provide training to primary healthcare providers Mumbai, September 19, 2024:…
“Every third Indian has fatty liver, which often predates Type 2 diabetes and other metabolic…
Removes a safety pin from the stomach lining through the minimal invasive technique of Endoscopy…